Last reviewed · How we verify

Standard of care neoadjuvant therapy

Galvanize Therapeutics, Inc. · FDA-approved active Small molecule Quality 5/100

Standard of care neoadjuvant therapy is a Small molecule drug developed by Galvanize Therapeutics, Inc.. It is currently FDA-approved for Various solid tumors as neoadjuvant pre-operative therapy (specific indication depends on cancer type and institutional standard of care). Also known as: Carboplatinum, Cipsplatin, Pemetrexed, Gemcitabine.

Standard of care neoadjuvant therapy refers to established pre-operative treatment regimens designed to shrink tumors before surgical resection.

Standard of care neoadjuvant therapy refers to established pre-operative treatment regimens designed to shrink tumors before surgical resection. Used for Various solid tumors as neoadjuvant pre-operative therapy (specific indication depends on cancer type and institutional standard of care).

At a glance

Generic nameStandard of care neoadjuvant therapy
Also known asCarboplatinum, Cipsplatin, Pemetrexed, Gemcitabine, Paclitaxel
SponsorGalvanize Therapeutics, Inc.
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Neoadjuvant therapy typically involves chemotherapy, targeted therapy, immunotherapy, or combinations thereof administered before primary surgical treatment. The goal is to reduce tumor burden, improve surgical outcomes, and potentially increase the likelihood of complete resection. The specific mechanism depends on the underlying drug class and cancer type being treated.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Standard of care neoadjuvant therapy

What is Standard of care neoadjuvant therapy?

Standard of care neoadjuvant therapy is a Small molecule drug developed by Galvanize Therapeutics, Inc., indicated for Various solid tumors as neoadjuvant pre-operative therapy (specific indication depends on cancer type and institutional standard of care).

How does Standard of care neoadjuvant therapy work?

Standard of care neoadjuvant therapy refers to established pre-operative treatment regimens designed to shrink tumors before surgical resection.

What is Standard of care neoadjuvant therapy used for?

Standard of care neoadjuvant therapy is indicated for Various solid tumors as neoadjuvant pre-operative therapy (specific indication depends on cancer type and institutional standard of care).

Who makes Standard of care neoadjuvant therapy?

Standard of care neoadjuvant therapy is developed and marketed by Galvanize Therapeutics, Inc. (see full Galvanize Therapeutics, Inc. pipeline at /company/galvanize-therapeutics-inc).

Is Standard of care neoadjuvant therapy also known as anything else?

Standard of care neoadjuvant therapy is also known as Carboplatinum, Cipsplatin, Pemetrexed, Gemcitabine, Paclitaxel.

What development phase is Standard of care neoadjuvant therapy in?

Standard of care neoadjuvant therapy is FDA-approved (marketed).

What are the side effects of Standard of care neoadjuvant therapy?

Common side effects of Standard of care neoadjuvant therapy include Chemotherapy-related toxicity (varies by regimen), Hematologic toxicity, Gastrointestinal toxicity, Cardiac toxicity (if anthracycline-based).

Related